Feb 28, 2022 | BALTIMORE – Complete Omics Inc, a multi-omics molecular diagnostics company, today announces the publication of a new peer reviewed paper in the academic journal CANCERS, presenting a new pipeline developed for validating and absolutely quantifying neoantigens from very limited amount of clinical samples.
Identifying and Quantifying Neoantigens derived from Human endogenous retroviruses (HERVs) — A new class of targets to expand the benefits of cancer immunotherapy.
Jan 29, 2022 | BALTIMORE – Complete Omics Inc, a multi-omics molecular diagnostics company, today announces the publication of a new peer reviewed paper in Science Advances journal, demonstrating the value of targeting antigens derived from human endogenous retroviruses (HERVs) specifically overexpressed by tumor cells for new immunotherapy approaches.
Our clinical proteomics pipeline enabling personalized cancer therapeutics, reported by numerous media
Complete Omics’ Clinical Proteomics team is proud to share with you the recent media coverage of our efforts in paving the way for the ultimate personalized cancer therapeutics. Our efforts toward achieving this ultimate goal of cancer treatment were reported by GenomeWeb, The Scientist, Precision Oncology News, News Wise, Fierce Biotech, etc. One of our clinical proteomics pipelines can help identify personalized cancer neoantigens that can be further targeted by a variety of therapeutic approaches, such as mRNA cancer vaccine, therapeutic peptide injection, engineering cell therapy, and here two bispecific antibody approaches.
Complete Omics Inc. (official website) – For years, personalized cancer therapeutics has been an ultimate goal for all cancer patients and doctors. Healthcare providers and scientists working across the biopharmaceutical industry have been tirelessly committed to bringing to patients more and more, better and better, personalized cancer therapeutic approaches.
Complete Omics has been a pioneer in multi-omics molecular diagnostics since founded and we are humbled and excited to share with you two of the milestones in personalized cancer diagnostics and treatment through our multi-omics platform that we have published on Science Immunology and Science.
NEW YORK – Researchers at Johns Hopkins University have developed a targeted mass spec method for measuring cancer-linked neoantigens.
Described in a study published last month in Cancer Immunology Research, the method could prove useful both for studying tumor immunology and in the development of personalized cancer immunotherapies, said Qing Wang, first author on the paper and founder and CEO of clinical omics firm Complete Omics.
NEW YORK (GenomeWeb) – Researchers in the lab of Johns Hopkins University professor Bert Vogelstein have identified a pair of potential peptide biomarkers for ovarian cancer.
Described in a study published this week in Proceedings of the National Academy of Sciences, the markers stem from efforts by the lab, which had traditionally focused on cancer genomics, to move more seriously into the proteomic and protein biomarker space, said Qing Wang, a faculty member in Vogelstein’s lab and first author on the study.
The peptide markers were validated using a selected-reaction monitoring system developed by Wang and his colleagues that uses light-labeled peptides and extensive fractionation to enable highly sensitive and reproducible quantitation of candidate biomarkers in plasma.
Cancer biomarkers are currently the subject of intense research because of their potential utility for diagnosis, prognosis, and targeted therapy. In theory, the gene products resulting from somatic mutations are the ultimate protein biomarkers, being not simply associated with tumors but actually responsible for tumorigenesis. In 2010, we developed the 1st pipeline for detecting and quantifying mutant protein as cancer specific biomarkers from human specimens, and it received a broad range of attentions from different disciplines of biomedical sciences [Ref. 1].